139
Participants
Start Date
April 30, 2008
Primary Completion Date
September 30, 2010
Study Completion Date
September 30, 2010
Octreotide Long Acting Release
Patients will receive the first dose of Octreotide LAR (30 mg) at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR (with an interval of 28 days between them), until first-line chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first.
Standard Treatment
Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
Biocâncer, Belo Horizonte
CEPON-Centro de Pesquisas Oncologicas, Florianópolis
Hospital Sao Lucas- Faculdade de Medicina da PUCRS, Porto Alegre
Clínica AMO, Salvador
Nucleo de Oncologia da Bahia, Salvador
Faculdade de Medicina do ABC, Santo André
Hosital Alemão Oswaldo Cruz, São Paulo
Hospital A C Camargo/ Fundação Antonio Prudente, São Paulo
Hospital das Clínicas - FMUSP, São Paulo
Instituto Arnaldo Vieira de Carvalho - IAVC, São Paulo
UNIFESP, São Paulo
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY